Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Orphan Drug Act Stories

2014-02-27 23:03:20

Resolution Promotes Awareness of Rare Diseases Sacramento, CA (PRWEB) February 27, 2014 Today at the state Capitol, Assemblymember Kevin Mullin (D-South San Francisco), in partnership with the California Healthcare Institute (CHI), presented House Resolution 32 recognizing Feb. 28 as Rare Disease Day in California. CHI is a nonprofit, public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical...

2014-02-25 08:32:12

EASTBOURNE, England, February 25, 2014 /PRNewswire/ -- Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, today announced receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), Office of Orphan Products Development, for AIMSPRO(R) for the treatment of systemic sclerosis (scleroderma). "The granting of Daval's request for Orphan Drug Designation represents a...

2014-02-14 23:21:13

MarketReportsOnline.com adds "US Orphan Drug Market Outlook 2018" report to its research store. Dallas, Texas (PRWEB) February 14, 2014 In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA...

2014-02-07 08:22:40

NEW DELHI, February 7, 2014 /PRNewswire/ -- KuicK Research releases "Global Orphan Drug Market Outlook 2018" research report offering comprehensive insight on recent trends, regulatory development related to US orphan drug market, Europe orphan drug market & Asia orphan drug market. Report also gives insight on more than 600 orphan drugs in clinical pipeline and 231 marketed orphan drugs. Global Orphan Drug Market Report Findings: - Orphan...

2014-02-04 23:00:35

EPI-743 phase 2b Friedreich's ataxia trial fully enrolled. Downingtown, PA (PRWEB) February 04, 2014 Edison Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to vatiquinone (EPI-743) for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-grants-edison-pharmaceuticals-epi-743-orphan-status-for-friedreichs-ataxia-243439351.html). Orphan status brings additional momentum and acceleration to the...

2014-02-04 00:21:05

EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb. 4, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia. Vatiquinone is the International Nonproprietary Name (INN) for Edison's EPI-743. The INN is a unique international name issued by the World Health Organization. It is used to identify the active pharmacological...

2013-10-07 08:25:49

Makovsky Health VP Bernstein Presents at 2013 DIA-NORD Conference in Bethesda, MD, October 7-9 NEW YORK, Oct. 7, 2013 /PRNewswire/ -- New health economics research assessing the current impact of the Orphan Drug Act (ODA) suggests the law continues to play a crucial role in stimulating drug development for small patient populations. The descriptive study is presented this week as a poster at the 3(rd) Annual DIA-NORD Conference on Rare Diseases & Orphan Products in Bethesda, MD....

2013-08-05 23:02:03

Bill Corr to Kick Off Conference 30 Years After Passage of Orphan Drug Act. Horsham, PA (PRWEB) August 05, 2013 Bill Corr, deputy secretary of the U.S. Department of Health and Human Services, will deliver the keynote address at the third annual U.S. Conference on Rare Diseases and Orphan Products in Bethesda, Md., on Oct. 7, 2013. Corr was vital in the passage of the Orphan Drug Act (ODA), serving as counsel to the U.S. House of Representatives’ Subcommittee on Health and the...

2013-07-23 23:04:05

Key Stakeholders in Rare Disease Community to Discuss the New Era in Health Care Bethesda, MD (PRWEB) July 23, 2013 Patient advocates, industry leaders, researchers, regulatory officials, investors and thought leaders dedicated to advancing the development of and access to therapies for rare diseases will come together for the third annual U.S. Conference on Rare Diseases and Orphan Products, held in Bethesda, Oct. 7–9. The conference is hosted by DIA and the National Organization for...

2013-07-16 23:17:16

In the new report, Global Markets For Orphan Drugs (PHM038D), from BCC Research, the global market for orphan drugs was valued at $82.6 billion in 2011 and nearly $86 billion in 2012. The report forecasts total market value to reach $112 billion in 2017, after increasing at a five-year compound annual growth rate (CAGR) of 5.4%. Wellesley, MA (PRWEB) July 16, 2013 In the new report, GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038D), from BCC Research (http://www.bccresearch.com), the global...